Terms: = Lung cancer AND LRIG3, Q6UXM1, 121227, ENSG00000139263, FLJ90440, KIAA3016, FLJ26573
5 results:
1. LMO7 and LIMCH1 interact with LRIG proteins in lung cancer, with prognostic implications for early-stage disease.
Karlsson T; Kvarnbrink S; Holmlund C; Botling J; Micke P; Henriksson R; Johansson M; Hedman H
Lung Cancer; 2018 Nov; 125():174-184. PubMed ID: 30429017
[TBL] [Abstract] [Full Text] [Related]
2. ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers.
Roskoski R
Pharmacol Res; 2017 Jul; 121():202-212. PubMed ID: 28465216
[TBL] [Abstract] [Full Text] [Related]
3. LRIG1 is a prognostic biomarker in non-small cell lung cancer.
Kvarnbrink S; Karlsson T; Edlund K; Botling J; Lindquist D; Jirström K; Micke P; Henriksson R; Johansson M; Hedman H
Acta Oncol; 2015; 54(8):1113-9. PubMed ID: 25813475
[TBL] [Abstract] [Full Text] [Related]
4. LRIG and cancer prognosis.
Lindquist D; Kvarnbrink S; Henriksson R; Hedman H
Acta Oncol; 2014 Sep; 53(9):1135-42. PubMed ID: 25180912
[TBL] [Abstract] [Full Text] [Related]
5. Unlocking biomarker discovery: large scale application of aptamer proteomic technology for early detection of lung cancer.
Ostroff RM; Bigbee WL; Franklin W; Gold L; Mehan M; Miller YE; Pass HI; Rom WN; Siegfried JM; Stewart A; Walker JJ; Weissfeld JL; Williams S; Zichi D; Brody EN
PLoS One; 2010 Dec; 5(12):e15003. PubMed ID: 21170350
[TBL] [Abstract] [Full Text] [Related]
